Table 1 shows the results of the last 10 years of studies on IL-17A in gastric cancer, and the table includes the types of studies, methods, cell sources, and main conclusions drawn from the studies. The existing studies suggest that IL-17A can promote or inhibit tumor progression through a variety of mechanisms (Table 1; Figure 1). The gene discussed is IL17A; the disease is neoplasm.